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6ABSTRACT
Summary  
1. Mitotic Activity Index (MAI) <10 versus 10 is an accurate and well reproducible 
prognosticator in lymph node negative breast cancer in women <71 years and 
superior to both the online program Adjuvant! and the Norwegian Breast Cancer 
Group in prognostication in lymph node negative breast cancer in women <55 years.  
2. In lobular invasive type breast cancers, a threshold of 5 is the most optimal 
threshold. 
3. Lymph vessel invasion defined by D2-40 or D2-40/p63 have no additional prognostic 
value to the MAI or Phosphohistone-H3 (PPH3). 
4. Ki67 assessed by interactive point-weighted morphometric analysis and especially 
digital image analysis, but not by subjective counts, is reproducible and 
prognostically strong. This casts serious doubt on guidelines advocating subjective 
counts for therapeutic decision making.
5.  PPH3 is the strongest prognosticator in the node negative breast cancers studied; 
Ki67-6.5% by DIA has additional prognostic value in patients with a low PPH3<13. 
Ki67-6.5% by DIA also has additional prognostic value in patients with a MAI < 10, 
but not in patients with MAI  10.
6. In daily practice, both the MAI, PPH3 and Ki67 should be assessed and the results 
carefully compared for adequate quality control and most accurate prognosis 
prediction for lymph node negative breast cancer patients.
Breast cancer is a leading cause of cancer mortality among women in the western world, 
second only to lung cancer. Since the mammography screening program in Norway started in 
1995, 70% and more of all new breast cancers diagnosed are small tumors  2cm in diameter 
without signs of regional or distant metastasis. Not surprisingly, the five year relative 
survival is very good (87.8%). Their improvement of absolute 10% survival with adjuvant 
systemic chemotherapy is less substantial than that for lymph node-positive patients. Both 
7the benefits and disadvantages of this 10% survival improvement must be considered when 
deliberating adjuvant systemic therapy (1, 2) and prognostic/predictive features are important 
in these decisions. Often, a combination of features is used in the decision making process 
for adjuvant systemic therapy, where tumour diameter, oestrogen receptor, grade and also 
age play a major role (3, 4). These guidelines identify 80% or more of all node-negative 
patients as high risk, although only ~15% of these patients die from metastatic disease 
without adjuvant treatment. This means that 65% of these patients are over-treated. On a 
world-wide basis, a more sensitive and specific prognosticator could therefore prevent 
enormous unnecessary suffering. 
Proliferation markers such as the Mitotic Activity Index (MAI), Phosphohistone-H3 
(PPH3) and Ki67 are prognostically stronger than classical prognosticators and multivariate 
guideline predictors, as shown in many prospective and retrospective (also multicenter) 
analyses (5-7). This is also true for the Norwegian national NBCG guidelines, as we have 
recently shown (8). 
In the current PhD study we will address the following questions: 
1. What are the criteria required for well reproducible assessment of the MAI? 
2. What is the accuracy of MAI compared to other prognostic models such as the 
online program Adjuvant! and the guidelines from Norwegian Breast Cancer Group 
(NBCG)?  
3. Is the prognostic threshold for proliferation in invasive breast cancers of the lobular 
invasive type the same as for ductal type invasive cancer? 
4. Does lymph vessel invasion have additional prognostic value to the MAI? 
85. Ki67 has recently been added to the national therapeutic decision making algorithm 
of the St Gallen and the Norwegian Breast Cancer Group guideline, but they do not 
give standard operating procedures how Ki67 must be determined. We therefore 
have analyzed the reproducibility and prognostic value of different methods to 
assess Ki67 expression. 
6. Finally, we will compare the prognostic value of the MAI, PPH3 and Ki67 with 
each other and with other prognostic factors. 
In the first article (Breast Cancer Res Treat. 2009 May; 115(2):241-54), we give a 
review of the literature, describing that proliferation of the primary tumour measured by the 
MAI is the strongest prognosticator. We also describe protocols, reproducibility and pitfalls 
in assessment of proliferation in node-negative breast cancer. In subsequent studies from our 
group (10), it was shown that Phosphohistone-H3 (PPH3) is a strong alternative for the MAI, 
and also can be measured by digital image analysis. This is a further extension of previous 
studies on automated counting of mitoses in tissue sections (11, 12). We also compare the 
prognostic value with alternative molecular prognostic markers. However, at the time of 
writing the review, the MAI was the most widely available and used method in the world to 
assess proliferation in breast cancer. Finally, we also describe possible error sources. When 
these factors are taken into account, the MAI can be well reproducible and has overriding 
prognostic significance (8, 13).  
9In the second article (J Clin Oncol 2010; 29(7):852-858), our aim was to assess the strength 
of MAI as compared with other models of prognostication in 516 lymph node negative breast 
cancer less than 55 years of age with a median follow-up of 118 months. Thresholds were set 
for MAI at <3, 3, Adjuvant! at <95%, 95% and NBCG features deciding adjuvant 
systemic treatment or not (lymph-node negative and ER positive with either: pT1, grad 1, all 
ages or: pT1a-b, grade 2-3,  35 years). All models were found to be prognostically 
significant, but with multivariable analysis, the MAI was prognostically stronger than both 
Adjuvant! and NBCG. Furthermore, stratification by MAI identified subgroups with different 
prognosis, indicating possible over- and undertreatment of T1-3N0M0 breast cancer patients 
<55 years.   
More than 80% of invasive breast cancers are of the ductal histologic type. Proliferation has 
been evaluated in node-negative breast cancer patients in general. However, studies on 
lobular invasive cancers are rare. In the third article (Breast Cancer Res Treat. 2010 
May; 121(1):35-40), we therefore evaluated prospectively the value of proliferation 
measured by the MAI compared with other classical prognostic factors in 121 lymph node 
negative invasive lobular cancers (ILCs) without systemic adjuvant treatment from the large 
Multicenter Morphometric Mammary Cancer Project (MMMCP). The 121 patients had 83 
months median follow-up time. Cases were subtyped in accordance with WHO-2003 criteria, 
supplemented by E-cadherin immunohistochemical analysis in cases with non-classical 
morphology. We found that solid/alveolar ILCs subtype (n=17) had a worse 10-year survival 
(50%) than other ILCs subtypes (n=104; 83%, P<0.0001). Furthermore, the MAI (but not 
nuclear grade or tubule formation) with a threshold of 0-5 versus >5 was prognostic in the 
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lobular invasive cancers (contrasting MAI<10 versus 10 in breast cancers in general), 85 
and 54% 10-year survival, respectively (P<0.0001). 
In the fourth article (Mod Pathol. 2011 Apr; 24(4):502-11), we investigated whether 
PhosphoHistone-H3 (PPH3) assessed proliferation and lymph vessel invasion (LVI) by D2-
40 are prognostic. Lymph vessel invasion has been propagated as a prognostic factor for 
many decades, but the assessment in conventional Hematoxylin-Eosin stained sections is 
poorly reproducible. D2-40 immunostaining can improve this, but myoepithelial D2-40-
expression in small ducts completely filled by solid-pattern ductal carcinoma in situ can 
mimic lymphovascular invasion. As myoepithelial cells are also p63 positive, we have 
investigated whether LVI identified by combined D2-40/p63 is stronger prognostically than 
by D2-40 alone and whether it has independent prognostic value to PPH3. In 240 operable 
T1-2N0M0 node negative invasive breast cancer patients less than 71 years with long-term 
follow-up and without adjuvant systemic treatment, PPH3 was determined by quantitative 
immunohistochemistry and LVI by D2-40/p63 double immunohistochemical staining. 
Correlation analysis between the clinico-pathologic factors and LVI, and univariate and 
multivariate prognostic survival analysis using recurrence free (RFS) and distant metastases 
overall survival (DM-OS) were performed. With median 117 (range: 12-192) months follow-
up, thirty-six patients (15%) developed and 28 (12%) died of distant metastases. Ten of the 
sixty-one patients (16%) with cancer cells surrounded by D2-40 were p63 positive and none 
of these “false LVI” recurred. D2-40+/p63- LVI occurred in 51/239 (21%) cases and 
correlated with grade, MAI, PPH3, oestrogen receptor (ER), cytokeratin 14 (CK14) and 
Herceptin (HER2/neu). D2-40+/p63- LVI was strongly prognostic, but far more in women 
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55 than those <55 years (P <0.0001 and 0.04). With multivariate analysis, PPH3 assessed 
proliferation was the strongest single prognosticator. LVI had additional prognostic value to 
PPH3 but only in women 55. For this group, where PPH3 13, patients without/with LVI 
had 10 year survival rates of 83% and 50% respectively (Hazard Ratio LVI=HR-LVI=3.0, 
P=0.04, HR-PPH3=6.9, P=0.002). Where age was <55, only PPH3 had independent 
prognostic value. Combinations of other features had no additional value to PPH3. In 
conclusion, in operable T1-2N0M0 invasive breast cancer patients 55 years with PPH3 13, 
D2-40+/p63- defined LVI identifies a subgroup with a very high risk of distant metastases. 
In the fifth article, submitted Histology September, 2011, we set out to evaluate the 
proliferation factor Ki67 in node negative breast cancer. Others have found that Ki67 is 
prognostic, but immunohistochemical and measurement procedures differ between 
laboratories. We compared the reproducibility and prognostic value of different Ki67 
measurement methods. In 237 T1-2N0M0 breast cancers without adjuvant systemic treatment, 
standardized and fully automated immunohistochemistry was used. The percentages of Ki67 
positive nuclei were assessed using conventional counts and a “quick scan” rapid estimate by 
independent pathologists, computerized interactive morphometry (CIM) and automated 
digital image analysis (DIA). Reproducibility was studied by duplicate blinded assessments. 
Using univariate and multivariate survival analyses, the prognostic value of widely accepted 
Ki67 thresholds (10, 15%, 20%) and other objective thresholds indicated by Receiver 
Operating Curve (ROC) analysis were studied. The Ki67 counts by two pathologists and 
their corresponding optimal prognostic thresholds varied greatly (4% and 14%). Quick scan 
rapid estimates were poorly reproducible and not prognostic. CIM-Ki67 were well and DIA-
Ki67 very well reproducible and strongly prognostic (P<0.0001). DIA-Ki67 with a ROC-
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selected threshold of 6.5% was the strongest prognosticator. We conclude that in node 
negative breast cancer without adjuvant systemic treatment, Ki67% by digital image analysis 
but not subjective counts is reproducible and prognostically strong. This casts serious doubt 
on therapeutic guidelines using subjective counts of Ki67. 
  
In the sixth article, manuscript October, 2011, we further analysed the reproducibility and 
prognostic value of Ki67 versus Mitotic Activity Index (MAI) and Phosphohistone-H3 
(PPH3); these were compared with classical prognostic and predictive factors (tumour size, 
steroid receptors and HER2/neu). In total of 237 T1-2N0M0 breast cancers not undergoing 
systemic adjuvant treatment, formalized MAI assessment, strictly standardized and fully 
automated quantitative immunohistochemistry for Ki67 and PPH3 were used. The 
percentages of Ki67 positive nuclei were assessed independently by two pathologists using 
conventional counts, by computerized interactive morphometry (CIM) and by automated 
digital image analysis (DIA). Receiver Operating Curve (ROC) analysis was used to 
objectively assess the optimal threshold of continuous variable such as Ki67. Section 
thickness was measured to increase standardization of Ki67 IHC. Section thickness had a 
low coefficient of variation, indicating that this potential error source can be kept minimal. 
ROC analysis showed that a DIA-Ki67 threshold of 6.5% had optimal and strongest 
prognostic value and added prognostically to PPH3. None of the other biomarkers of 
clinicopathologic variables added prognostically to this PPH3/Ki67 combination. However, 
when PPH3 is replace by MAI the prognostic value is nearly the same. We conclude that in 
node negative breast cancer without adjuvant systemic treatment, Ki67 assessed by digital 
image analysis in the periphery of the tumour with a threshold of 6.5%, is prognostically 
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strong. The combination of either PPH3/Ki67 or MAI/Ki67 overshadowed the prognostic 
value of all other features.   
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MAI Mitotic Activity Index 
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PPH3 Phosphohistone H3 
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1. INTRODUCTION 
1.1 Breast cancer epidemiology 
Breast cancer is a leading cause of cancer mortality among women in western world, second 
only to lung cancer. In Norway, the age-specific incidence rate of breast cancer has more 
than doubled from 37.3 to 76.7/100,000/year between 1955 and 2003 (Figure 1). The 
incidence increases by age and reaches a peak between 65 and 69 years. In 2008, 2753 new 
women were diagnosed with breast cancer in Norway and constituted 23% of all 
malignancies when all ages were grouped together. The cumulative risk for women to 
develop breast cancer is 8.1% and about one in twelve women in Norway will develop the 
disease by the age of 75 (14). 
Figure 1. Time trends for age-standardized incidence rate in Norway for selected cancers in 
women (from reference 14). 
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Since the mammography screening program for women age (51-69 years) in Norway started 
in 1995, the incidence of breast cancer has sharply increased, but later leveled off. This is 
mainly due to the increased early detection of prognostically favorable tumours in the 
population screening material. As a result, 70% and more of all new breast cancers 
diagnosed in Norway since mammography screening started, are small tumours (i.e.,  2cm 
in diameter) without signs of regional or distant metastasis. Not surprisingly, the five year 
relative survival is very good (87.8%) (14). On the other hand, an increased age adjusted 
mortality of 23% more than 20 years after diagnosis has been found for all stages of breast 
cancer (14). Whether mammography screening and early detection of breast cancer will 
result in reduced mortality, is still a matter of (sometimes hot) debate. 
1.2 Proliferation and breast cancer 
As mentioned, the prognosis of patients with lymph node-negative breast cancer is relatively 
good (20-30% die from recurrent disease). The improvement of survival of lymph node-
positive patients due to adjuvant systemic therapy is about 25% absolute and 50-60% 
relative. However, for early lymph node negative breast cancer patients the survival 
improvement is much less substantial; the typical 15-year survival difference for treated and 
untreated patients is approximately 10% absolute and 15-30% relative. The benefits of this 
10% absolute improvement in survival must be considered against the context of the 
disadvantages of adjuvant systemic therapy (1, 2) and prognostic/predictive features are 
important in these decisions.  
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Often, a combination of features is used in the decision making process for adjuvant 
systemic therapy, where tumour diameter, oestrogen receptor, grade and also age play a 
major role (3, 4). A simplified version of this is the Sankt Gallen guideline (15), which 
identifies 85% or more of all node-negative patients as high risk. As only ~25% of these 
patients die from metastatic disease without adjuvant treatment in the 20 years following the 
diagnosis, the remaining 60% of patients receiving adjuvant systemic treatment are over-
treated as they would have remained alive and well anyway. On a world-wide basis, a more 
sensitive and specific prognosticator could therefore prevent enormous unnecessary 
suffering. 
Proliferation markers such as the mitotic activity index (MAI) and Thymidine 
Labeling Index (TLI) are prognostically stronger than classical prognosticators and 
predictors, as shown in many prospective and retrospective (also multicenter) analyses (5-7). 
Moreover, while studies evaluating the role of individual genes regulating these processes 
have increased our knowledge of the complex process of proliferation, the functional end 
result is dividing cells. This is microscopically visible as mitotic figures which have 
remained the most important prognostic factor so far (16). Moreover, the MAI is widely 
available, easy to use, inexpensive, and highly reproducible (13, 17). A large, multicenter 
prospective long follow-up study (13) showed that lymph node negative patients with high 
proliferation (MAI  10) have the same poor outcome as women with 1-3 positive lymph 
nodes (Figure 2). 
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Figure 2. Results from the MMMCP study, showing that lymph node negative patients with 
high proliferation (MAI  10) have the same poor outcome as women with 1-3 positive 
lymph nodes (adapted from reference 13) 
Moreover, in two independent studies, adjuvant chemotherapy was significantly beneficial to 
patients with rapidly proliferating tumours but not to patients with slowly proliferating 
tumours (18, 19) (Table 1).
Table 1. Adjuvant chemotherapy in node negative breast cancer patients is significantly 
beneficial to patients with rapidly proliferating tumours but not to patients with slowly 
proliferating tumours (modified from Janssen et al (18)). 
 10-year survival (%)  
Adjuvant Systemic 
Chemotherapy  
 Yes No 
Probability of no 
difference 
Low 
proliferaton 
(MAI < 3) 92 94 0.63 
High 
proliferation 
(MAI  3) 87 75 0.003 
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Although proof of a crucial prognostic and predictive role of proliferation is thus very 
strong, two small studies did not confirm this (20, 21). Smaller studies inevitably carry the 
risk for selection bias, but other error sources should also be considered. In order to explain 
these discrepancies we have analyzed possible error sources together with potentially 
powerful immuno-histochemical alternatives for the MAI. Validation of a prognostic test in 
independent multicenter test-set studies is mandatory for a diagnostic or therapeutic clinical 
laboratory test (22, 23).  
One objection against mitotic activity index (MAI) assessment is that it is subjective 
and not well reproducible. Much work has been done since the early 1980s regarding the 
factors causing lack of reproducibility and how to avoid pitfalls and these will be discussed 
in the first article. In the second article, we will compare the strength of MAI with other 
models of prognostication of T1-3N0M0 breast cancer patients and in the third article, we will 
study the prognostic significance of the MAI in a special subtype of invasive breast cancers: 
the lobular invasive cancers. In the other articles, the MAI and two other proliferation 
biomarkers (Phosphohistone-H3 and Ki67) will be studied as well. 
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2. Materials and Methods 
2.1 Patients 
The lymph node negative breast cancer and lobular invasive cancers described in the second 
and third article were from the prospective national Dutch Multicenter Morphometric 
Mammary Carcinoma Project and approved by the Ethics Committee of the Free University 
Medical Center (Amsterdam, the Netherlands) and all collaborating hospitals. In this study, 
3,474 consecutive patients with primary breast cancer were diagnosed and treated in 34 
collaborating hospitals between October 1987 and December 1989. Median follow-up time 
was 118 months (i. e., 9.8 years; range, 8 to 185 months). In the present PhD study, 516 
patients with invasive T1-3 breast carcinoma (article 2) and 121 patients with invasive lobular 
carcinoma (article 3), all with LN-negative status, and age less than 55 years from the 
MMMCP were analyzed. All patients underwent mastectomy or breast-conserving surgery in 
addition to axillary LN dissection; the median number of LNs investigated was 14. Whole-
breast radiotherapy was given to patients who underwent breast-conserving therapy. Because 
all patients were axillary node negative, they received radiotherapy to regional nodal fields 
only if they had medially localized tumours. Following the national guidelines during the 
enrollment period, none of these LN-negative patients received any form of adjuvant 
systemic chemotherapy. 
The Stavanger material used in articles 4, 5 and 6 was a part of a large prospective 
multicenter international breast cancer study “Prognostic and predictive aspects of breast 
cancer”, started in 1975. The Stavanger part of this project was approved by the Regional 
Ethics Committee, The Norwegian Social Science Data Service, and the Norwegian Data 
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Inspectorate. In the studies described in articles 4, 5 and 6 we analyzed patients diagnosed 
with invasive, operable, lymph node negative (T1-2N0M0) breast cancer at the Stavanger 
University Hospital, between January 1, 1990 and December 31, 1997. None of these 
patients received adjuvant systemic chemotherapy. 
 2.2 Pathology
Post-surgical size of the tumor (pT) was measured in the fresh specimens; the tumors were 
cut into slices of 0.5 centimeter, fixed in buffered 4% formaldehyde and embedded in 
paraffin. Four micrometers thick paraffin sections were cut and stained with hematoxylin and 
eosin (the Norwegian breast cancer sections were also stained with saffran). Histologic grade 
and type were assessed in the many participating centers and independently reviewed by 
three experienced breast pathologists. Invasive lobular cancers were defined using the World 
Health Organization (WHO) criteria (24) as cancers composed of non-cohesive cells 
individually dispersed or arranged in a single-file linear pattern (often referred to as ‘Indian 
filing’), often associated with lobular carcinoma in situ (LCIS), frequently with a diffuse 
growth pattern or cell infiltrate, and having a concentric “targetoid” pattern around normal 
ducts. Grade was assessed, again according to the WHO criteria using MAI 0-5=1, 6-10=2 
and >10 as 3, nuclear atypia as mild=1, moderate=2 and marked=3, and tubule formation as 
much (>75%)=1, minimal (<10%)=3 and intermediate (10-75%)=2. A careful review of type 
in cases of adequate follow-up revealed that 1812 cancers were ductal; 113 ductal combined 
with other types (but non-lobular); 201 lobular invasive; 23 tubular; 22 colloid; 11 
medullary, and 2 were papillary (total=2184). As the non-lobular non-ductal cancers were 
relatively rare and also had a much better prognosis than the ILCs and IDCs, they were not 
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further considered in the present studies. Of the 201 lobular invasive cancers, 121 were 
LNneg, and sub-typed independently by two of us (EG, JB). LCIS was characterized by 
extended lobules with a typical solid cell pattern without a clear lumen, consisting of cells 
with remarkably round and regular nuclei with regular spacing, often with somewhat more 
cytoplasm than in ductal cancers and frequently containing cytoplasmic vacuoles. The 
pleomorphic and solid variants may cause differential diagnostic problems with classical 
(“Indian filing”) ILC on the one hand (for the pleomorphic ILCs) and ductal grade 3 cancers 
(for the solid ones) on the other. To avoid this, using the WHO 2003 criteria, we defined 
ILCs as pleomorphic if they had clearly large and round, rather than molded, small nuclei 
located in Indian files of one, or at maximum, focally two cells thickness. To avoid a false 
inclusion of ductal grade 3 cancers, the following characteristics of LCIS or Indian filing 
with targetoid growth pattern should be present to classify a cancer as an ILC, solid subtype. 
Presence of extensive necrosis occurred in one solid cancer which is unusual in solid ILCs, 
and therefore this case was excluded as well, also due to the E-cadherin staining result (see 
below). In all cases classified as pleomorphic or solid, E-cadherin staining was done using 
normal glands in the same sections as internal controls. The non-lobular ductal combinations 
were regarded as ductal but the ductulo-lobular cancers were regarded as a lobular subtype 
variant; they had the same survival as the ductal and the non-solid-non-pleomorphic lobular 
subtype cancers. The resection margins in the biopsies were evaluated as free or not free of 
tumour. Oestrogen receptor value (ER) was assessed in reference laboratories with the 
charcoal technique (cut off 10 fmol/mg protein). For the ER negative cases, 
immunohistochemical analysis was done. 
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2.3 Immunohistochemistry and measurement of section thickness 
Antigen retrieval and antibody dilution were optimized prior to the onset of the studies. 
Sections were deparaffinized in xylene and rehydrated in decreasing concentrations of 
alcohol. Antigen was retrieved with a highly stabilized retrieval system (ImmunoPrep, 
Instrumec, Oslo, Norway) using 10 mM TRIS/1 mM EDTA (pH 9.0) as the retrieval buffer. 
Sections were heated for 3 min at 110oC followed by 10 min at 95oC and cooled to 20º C. 
Rabbit polyclonal anti-phosphohistone H3 (ser 10) (Upstate #06-570; Lake Placid, NY) was 
used at a dilution of 1:1500. Ki67 (clone MIB-1, DAKO, Glostrup, Denmark) was used at 
dilution 1:100. ER (clone SP1, Neomarkers/LabVision, Fremont, CA, USA) was used at a 
dilution 1/400. PR (clone SP2, Neomarkers/LabVision) was used at a dilution of 1/1000. 
Anti-phophohistone H3 was incubated for 60 min at 22° C. A primary antibody cocktail of 
p63 (DAKO, clone 4A4) and D2-40 (DAKO, clone D2-40) were used at final dilution of 
1:1200 and 1:200, respectively. All other antibodies were incubated for 30 min at 22°C. For 
HER2 assessments, the HercepTest kit (DAKO) was used according to the manufacturer’s 
FDA-approved procedures. HercepTest 2+ and 3+ cases were retested with the PathVysion 
(Vysis, Downers Grove, IL, USA) assay following the manufacturer’s FDA-approved 
protocols. Only HER2 amplified cases were regarded as positive. Dako antibody dilutent 
(S0809) being used. The EnVisionTM Flex detection system (Dako, K8000) was used for 
visualization. Sections were incubated for 5 min with peroxydase-blocking reagent (SM801), 
20 min with the EnVisionTM FLEX/HRP Detection Reagent (SM802), 10 min with 
EnVisionTM FLEX DAB+ Chromogen (DM827)/EnVisionTM FLEX Substrate Buffer 
(SM803) mix and 5 min with EnVisionTM FLEX Hematoxylin (K8008). The slides were then 
dehydrated and mounted. All immunohistochemical stainings were performed using Dako 
Autostainer Link 48 instrument and EnVisionTM FLEX Wash Buffer (DM831). 
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The section thickness was measured in two different ways. First, in 10 randomly selected 
cases the distance of the lowest and highest focal plane of the bottom and the top of the Ki67 
stained section was measured using a 100 times microscope objective (25). Secondly, in 
folds of the Ki67 sections, the section thickness could be measured as described by Elias et al 
(26). There was a reasonably good agreement between the two methods with a coefficient of 
variation of the section thickness being less than 7%. 
For assessment of lymphatic invasion (LVI), the sections were evaluated with double 
staining (D2-40 (cytoplasmic) and p63 (nuclear)). D2-40-stained slide was assessed for LVI 
without knowledge of the LVI status based on the original H&E slide or originally reported 
findings. A lymph vessel that showed positive staining of the endothelium (cytoplasm) for 
D2-40 and surrounded the tumour cells was diagnosed as positive for LVI. p63 positive 
myoepithelial cell nuclei within such a structure excluded LVI. Interpretation of 
immunohistochemical results was made without knowledge of clinical outcome and the 
status of other prognostic variables.  
Assessment of the percentages of Ki67- and PPH3-positive nuclei  
The Ki67 counts were done as follows. First, the whole section was scanned with low 
magnification and in the invasive parts the “Hot Spots” of high Ki67 expression identified. 
Then, in each of the hot spots with the subjectively highest Ki67 expression, the 
percentage of epithelial cancer nuclei with any Ki67 positivity was assessed with an 
objective of 40x (numeric aperture 0.75) in an area at specimen level of 1.59 mm2
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(following the counts for Mitotic Activity Index) . The hot spot with the highest 
percentage Ki67 positive nuclei thus obtained was used for each cancer. Two 
pathologists independently did the Ki67 evaluations. 
The PPH3 index was assessed by the same counting protocol as for the MAI in the same 
invasive peripheral epithelial cancer parts of the most PPH3-positive areas. Nuclei with fine 
granular PPH3 staining were not counted, as these cells are not in the G2 phase (27). PPH3-
rich areas are usually localized in the periphery (i.e., growing zone) of the cancers. If the 
PPH3 counts of two observers differed by more than 3 figures, the count was repeated with a 
multi-head microscope and a consensus score was obtained. 
2.4 Computer interactive morphometry 
Quantitative assessments have been shown to be better reproducible, but still interobserver 
variation may be considerable. This can be due to differences between different observers in 
classifying an object as immunohistochemically positive, or a lack of reproducibility due to 
selection bias by the observer (28). Selection bias may be overcome by systematic random 
sampling, both in the fields of vision within a relevant area, and in the selection of certain 
objects. We therefore performed morphometric analysis of Ki67 by means of the semi-
automatic interactive computerized QPRODIT system (Leica, Cambridge), as follows. At 
low magnification, the area with the subjectively highest Ki67 index where the counts had to 
be done was selected. This area was first marked with a black marker at the underside of the 
microscopic glass and then electronically demarcated. In that demarcated area, the Q-
PRODIT system automatically selects at random 300 fields of vision (FOVs). Then, at higher 
magnification the nuclei in each FOV were projected on the monitor, and Ki67 
immunoquantitation was performed at a final magnification of 400 (objective 40, numerical 
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aperture 0.75). In each field of vision selected systematically at random, one point of the 
smallest electronic grid available (i.e. two horizontal lines) in the QPRODIT system is used 
for point-weighted sampling. A sample of 300 points at the start of each measurement was 
used so that at least 150 nuclei were counted in each measurement area (average 235). At the 
magnification used, tumour cells could accurately be distinguished from other cells. The 
sample point of the test grid thus could be Ki67 positive, Ki67 negative or neither of the two. 
These latter points were ignored. The Ki67 percentage was defined as [(Ki67 positive)/ 
(Ki67 positive + Ki67 negative)] x 100. The total procedure takes about 20 minutes for an 
experienced person. Ten cases were measured twice and the results are well reproducible 
between different observers (R2=0.94).  
2.5 Digital image analysis 
In addition to performing subjective counts and computerized interactive morphometry, Ki67 
and PPH3 expression was also evaluated using the fully automated VIS digital image 
analysis (DIA) system (Visiopharm, Hørsholm, Denmark), using similar image processing 
principles as described before (29). Depending on the tumour diameter, two-ten square areas 
of each 1.59 mm2 with subjectively the highest Ki67 index were scanned at 20x 
magnification. A mask of tumour cells was semi-automatically created. Inside this mask blue 
(negative) and brown Ki67 positive nuclei were segmented using a Bayesian classifier. The 
Ki67 index was calculated using the areas of classified blue and brown nuclei. The square 
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with highest Ki67 index was used as the final result. Figure 3 illustrates the procedure. 
Figure 3.  Examples of Ki67 image analysis. a) Overview image of the whole slide with 1.59 
mm2 squares manually placed in the areas that subjectively show the highest number of 
positive cells. b) Rescan at 20x magnification of one of the squares in (a) showing a semi- 
automated mask (dotted line) of tumour cells. c) Tumour cells inside the mask in (b) are 
classified using a Bayesian classifier into negative nuclei, blue label, Ki-67 positive nuclei, 
yellow label and cytoplasm, red label. d) and e) Small section of b and c showing more 
details. The Ki-67 percentage is calculated on the basis of the area of the blue and yellow 
label. Note that only epithelial tumour cells are analyzed. Normal epithelium, stroma cells 
and leucocytes are excluded by the mask.  The square in (a) showing the highest percentage 
of Ki-67 positivity per 1.59 mm2 is used as the final result. 
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Not surprisingly, the reproducibility of the DAI-Ki67 and PPH3 counts by the 
automated digital image analysis on different days by different observers on 10 randomly 
selected cases was close to perfect (R2=0.99). 
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3.  AIMS OF THE THESIS 
Accurate and well reproducible prognostic factors are important for treatment decisions in 
breast cancer.   
The aims of our studies therefore were: 
1. Compare the prognostic power of Adjuvant! and the NBCG guidelines with the MAI. 
2. To assess proliferation and other prognostic factors in lymph node negative invasive 
lobular carcinoma; 
3. To clarify the prognostic value of D2-40 and D2-40/p63-defined lymph vessel invasion in 
lymph node negative breast carcinoma; 
4. To assess the reproducibility and prognostic value of the proliferation marker Ki67 
assessed by different determination methods and evaluated the multivariate independent 
value of Ki67, MAI and PPH3 in early (T1-2) lymph node negative breast carcinoma.  
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4.  RESULTS
Paper 1  
Baak JP, Gudlaugsson E, Skaland I, Guo LH, Klos J, Lende TH, Søiland H, Janssen 
EA, Zur Hausen A. Proliferation is the strongest prognosticator in node-negative breast 
cancer: significance, error sources, alternatives and comparison with molecular 
prognostic markers. Breast Cancer Res Treat. 2009 May; 115(2):241-54. 
Independent studies have shown that in node negative breast cancer patients less than 71 
years, the proliferation marker mitotic activity index (MAI) is the strongest, most well 
reproducible prognosticator and chemotherapy success predictor. The MAI should be 
determined in the periphery of the tumour. The MAI overshadows the prognostic value of 
tubule formation, nuclear atypia and thereby grade. An often used crude mitotic impression 
is much less prognostic than the MAI; strict adherence to the MAI protocol is therefore 
important. The prognostic value of the MAI is age dependent: although patients with a MAI 
10 always have a poor prognosis irrespective of age, a low MAI (<10) loses its favourable 
prognostic association in women >70 years. PPH3 counts are prognostically stronger than the 
MAI, and markers such as Cyclin-B and E2FR are promising, but must be validated.  
Compared with commercial prognostic gene expression signatures, the MAI is at 
least as strong prognostically, has far fewer false positive results and as such should be 
included as an independent feature in any lymph node negative breast cancer pathology 
report. The prognostic thresholds prescribed by the World Health Organization 
(WHO2003) of 0-5, 6-10 and > 10, are not correct for the node negative breast cancers. 
Rather, the most important prognostic threshold is <10 vs 10. Patients with low 
proliferation (MAI<3) do not benefit from adjuvant chemotherapy. 
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Paper 2 
Lende TH, Janssen EAM, Gudlaugsson E, Voorhorst FJ, Smaaland R, van Diest P, 
Søiland H, Baak JPA. In patients younger than age 55 years with lymph node-negative 
breast cancer, proliferation by mitotic activity index is prognostically superior to 
Adjuvant!. J Clin Oncol 2010; 29(7):852-858. 
In large multicenter prospective and retrospective studies, the MAI has proven to be a robust 
and reproducible prognostic factor in lymph node-negative patients younger than age 55 
years and also predicts the effect of adjuvant systemic therapy in this age group (18). 516 
lymph node-negative breast cancer patients age less than 55 years with a 118 months median 
follow-up were analyzed.  The concordance between MAI on one hand and the online risk 
model/calculator Adjuvant! and the Norwegian breast cancer group (NBCG) guidelines on 
the other hand, was fair ( = 0.35 and  = 0.29, respectively). Adjuvant!, NBCG, and MAI 
were all prognostically significant (P .001). In the univariate analysis, the 10-year BCSS of 
MAI <3 versus  3 was 95% v 71%, respectively, with a hazard ratio of 7.0. In multivariable 
analysis, MAI was superior to Adjuvant! and NBCG. The 10-year survival of Adjuvant! 
95% versus <95% was 91% v 74%, respectively, but stratification by MAI identified 
subgroups with different prognosis. Similar results occurred for NBCG and MAI. Adjuvant! 
and NBCG were not prognostic to each other.  
We conclude that MAI is superior to Adjuvant! and NBCG in prognostication of 
patients with lymph node-negative breast cancer younger than age 55 years. 
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Paper 3  
Gudlaugsson E, Skaland I, Janssen EA, van Diest PJ, Voorhorst FJ, Kjellevold K, zur 
Hausen A, Baak JP. Prospective multicenter comparison of proliferation and other 
prognostic factors in lymph node negative lobular invasive breast cancer. Breast 
Cancer Res Treat. 2010 May; 121(1):35-40 
Histologic subtype and MAI have independent prognostic value in node negative invasive 
lobular cancers. With a median follow up time of 83 months (range: 19-181), thirty of the 
121 (25%) ILC patients developed distant metastases and 27 (22%) died. None of the cases 
classified as solid/pleomorphic lobular were E-Cadherin or oestrogen receptor positive 
contrasting the other ILCs. The solid/ alveolar ILCs (n=17) had a worse survival (50%) than 
the other ILCs (n=104) (83%, P<0.0001). Mitotic Activity Index (MAI) (but not nuclear 
grade or tubule formation) was prognostic with a threshold 0-5 versus >5 (=MAI-5) 
(contrasting MAI<10 vs. 10 in breast cancers in general) (85% and 54% survival, P < 
0.0001). With multivariate analysis, only ILC-subtype and MAI, and none of the other 
characteristics, had independent, prognostic value.  
 We conclude that histologic subtype of invasive lobular cancers and MAI have 
independent prognostic value in node negative invasive lobular cancers. However, the 
essential prognostic threshold is 5, not 10. 
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Paper 4  
Gudlaugsson E, Skaland I, Undersrud E, Janssen EA, Søiland H, Baak JP. D2-40/p63 
defined lymph vessel invasion has additional prognostic value in highly proliferating 
operable node negative breast cancer patients. Mod Pathol. 2011 Apr; 24(4):502-11 
Phosphohistone H3 assessed proliferation has strong prognostic value. Lymph vessel 
invasion by D2-40 is also prognostic, but D2-40-positive myoepithelial expression in small 
ducts completely filled by solid-pattern ductal carcinoma in situ can mimic lymphovascular 
invasion. As myoepithelial cells are also p63-positive, we have investigated whether lymph 
vessel invasion identified by combined D2-40/p63 expression is stronger prognostically than 
by D2-40 expression alone, and whether it has independent prognostic value to 
phosphohistone H3. In 240 operable T1–2N0M0 node negative invasive breast cancer patients 
<71 years, phosphohistone H3 was determined by quantitative immunohistochemistry and 
lymph vessel invasion by D2-40/p63 double immunostaining. Correlation analysis between 
the clinico-pathologic factors and lymph vessel invasion, and univariate and multivariate 
prognostic survival analysis were performed. With median 117 (range: 12–192) months 
follow-up, 36 patients (15%) developed and 28 (12%) died of distant metastases. Ten of the 
61 patients (16%) with cancer cells surrounded by D2-40 were p63-positive and none of 
these ‘false lymph vessel invasion’ recurred. D2-40-positive/ p63-negative lymph vessel 
invasion occurred in 51/239 (21%) cases and correlated with grade, mitotic activity index, 
phosphohistone H3, ER, cytokeratin14, and HER2. D2-40-positive/p63-negative lymph 
vessel invasion was strongly prognostic, but far more in women 55 than those <55 years 
(P<0.0001 and 0.04, respectively). With multivariate analysis, phosphohistone H3 
proliferation was the strongest single prognosticator. Lymph vessel invasion had additional 
prognostic value to phosphohistone H3 only in women 55 years. This group of patients, 
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without/with lymph vessel invasion, had 10-year survival rates of 83 and 50%, respectively 
(hazard ratio-lymph vessel invasion = 3.0, P = 0.04; hazard ratio-phosphohistone H3 = 6.9, P 
= 0.002). Where age was <55 years, only phosphohistone H3 had independent prognostic 
value. Combinations of other features had no additional value. 
We conclude that T1–2N0M0 invasive breast cancer patients 55 years with 
phosphohistone H313, D2-40-positive/p63-negative defined lymph vessel invasion 
identifies a subgroup with a high risk of distant metastases. Lymph Vessel Invasion 
defined by D2-40 alone, gave many false positive lymph-vessel invasions and none of these 
‘false lymph vessel invasion’ recurred.  
Paper 5  
Gudlaugsson, Skaland I, Janssen EAM, Feng W, Shao Z, Malpica A and Baak JP. 
Automation of measurement of Ki67 proliferation is essential for reproducible and 
accurate prognosis prediction in T1-2N0M0 breast cancer. Manuscript Sept, 2011 
The proliferation factor Ki67 is prognostic in early breast cancer, but immunohistochemical 
determinations differ between laboratories, measurements not being standardized or 
automated. In 237 T1,2N0M0 breast cancers without adjuvant systemic treatment, formalized 
MAI assessment, strictly standardized and fully automated quantitative Ki67 
immunohistochemistry were used. The percentages of Ki67 positive nuclei were assessed 
independently by two pathologists using conventional counts, by computerized interactive 
morphometry (CIM) and by automated digital image analysis (DIA). Reproducibility was 
demonstrated by duplicate blinded assessments. Using univariate and multivariate survival 
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analyses, the prognostic value of widely accepted Ki67 thresholds (10%, 15%, 20%) and 
other thresholds indicated by Receiver Operating Curve analysis were studied. Quick scan 
rapid estimates of Ki67 were poorly reproducible and not prognostic. The Ki67 counts by 
two pathologists and their corresponding optimal prognostic thresholds varied greatly (4% 
and 14%). However, DIA-Ki67 and CIM-Ki67 were reproducible and highly prognostic 
(P<0.0001). DIA-Ki67 with a threshold of 6.5% was the strongest prognosticator.   
We conclude that in node negative breast cancer without adjuvant systemic 
treatment, Ki67 in the periphery of the tumour assessed by digital image analysis, but not 
subjective counts, was reproducible and prognostically strong.  This casts serous doubt on 
therapeutic guidelines using subjective counts of Ki67. 
Paper 6 
Gudlaugsson, Skaland I, Janssen EAM, Feng W, Shao Z, Malpica A and Baak JP. 
Multivariate comparison of the prognostic value of the proliferation markers Mitotic 
Activity Index, PhosphoHistone-3, Ki67, steroid receptors, HER2, basal cell type and 
classical prognostic factors in T1-2N0M0 breast cancer. Manuscript Oct, 2011 
The reproducibility and prognostic value of Ki67 versus Mitotic Activity Index (MAI) and 
Phosphohistone-H3 (PPH3) is largely unknown and have not been studied. Further, these 
were compared with classical clinico-pathologic prognostic and predictive factors (tumour 
size, oestrogen receptor and HER2/neu). In 237 T1,2N0M0 breast cancers without systemic 
adjuvant treatment, formalized MAI assessment was performed. We used strictly 
standardized and fully automated quantitative immunohistochemistry for Ki67, PPH3, 
oestrogen (ER) and progesterone receptor (PR), HER2, cytokeratins 5 and 6, and automated 
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digital image analysis (DIA) for measuring PPH3 and Ki67. Receiver Operating Curve 
(ROC) analysis was used to objectively assess the optimal threshold of continuous variable 
such as Ki67. Section thickness was measured to increase standardization of Ki67 IHC. 
Univariate and multivariate survival analyses were used to compare the different 
proliferation and other well established clinico-pathologic prognostic factors. 
Section thickness had a low coefficient of variation, indicating that this potential error 
source can be kept minimal. ROC analysis showed that a DIA-Ki67 threshold of 6.5% had 
optimal and strongest prognostic value and added prognostically to PPH3. None of the other 
biomarkers of clinicopathologic variables added prognostically to this PPH3/Ki67 
combination. However, when PPH3 is replace by MAI the prognostic value is nearly the 
same.  
We conclude, that in node negative breast cancer without adjuvant systemic 
treatment, Ki67 assessed by digital image analysis with a threshold of 6.5%, is 
prognostically strong. The combination of either PPH3/Ki67 or MAI/Ki67 overshadowed 
the prognostic value of all other features.   
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5. CONCLUSIONS OF THIS THESIS
On the basis of the literature studied and the research studies described in this PhD thesis, the 
following conclusions are drawn. 
1. Mitotic Activity Index is an accurate prognostic factor in lymph node negative 
breast cancer in women under 71 years old. The MAI can be well reproducible 
when the MMMCP protocol for tissue processing, sectioning, staining and 
counting is carefully kept. The strongest prognostic threshold is <10 versus 10, 
but patients with MAI < 3 still have a slightly better prognosis than those with 3 
MAI  10.  
2. The MAI is superior to Adjuvant! and NBCG in prognostication of patients with 
lymph node-negative breast cancer younger than age 55 years and identifies a high-
risk subgroup of patients classified as low risk and a low-risk subgroup classified 
as high risk with conventional prognostication models. 
3. The MAI is also prognostic in node negative breast cancers of the lobular invasive 
type, but the threshold of 10 is too high. A threshold of 5 is the most optimal 
threshold. The histologic subtype of invasive lobular cancer and the MAI have 
independent prognostic value. 
4. Lymph vessel invasion defined by D2-40 is not specific enough; a double staining 
of D2-40 and p63 is better suited as it distinguishes ductal carcinoma in situ from 
real lymph vessel invasion. However, D2-40 and D2-40/p63 defined lymph vessel 
invasion have no additional prognostic value in node negative breast cancer 
patients under 71 years old. 
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5.  In node negative breast cancer without adjuvant systemic treatment, Ki67 assessed 
by digital image analysis or interactive point-weighted morphometry, but not by 
subjective counts, was reproducible and prognostically strong. Digital image 
analysis assessed Ki67 expression gives the best reproducible results and is also 
prognostically strongest. The optimal Receiver Operating Curve (ROC) detected 
prognostic threshold is <6.5% versus 6.5%. The threshold of the Norwegian 
Breast Cancer Group of 15%, for node positive breast cancers, is prognostically 
much less strong than the threshold of 6.5 for the node negative patients. 
6. CIM supported Ki67 evaluation is also strongly prognostic and well reproducible 
with a threshold of 9.5% 
7. Subjective counts between different pathologists are not well reproducible. This 
casts a serious doubt on the NBCG guidelines of a fixed 15% Ki67-threshold, 
unless the measurements are done by DIA or CIM. 
8. A quick global scan with a rapid Ki67 estimate is not reproducible at all, and not 
prognostic. The use of such strategy in routine surgical pathology must be regarded 
as a serious professional violation. 
9. As single variables, the MAI or PPH3 are prognostically stronger than Ki67-6.5% 
by digital image analysis.  
10. PPH3 is the strongest prognostic factor and Ki67-6.5% by DIA has additional 
prognostic value in patients with a low PPH3<13 per 1.59 mm2 at specimen level. 
In daily practice, all three proliferation factors (MAI, PPH3 and Ki67) should be 
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assessed and the results carefully compared for adequate quality control and to get 
the most accurate prognosis and therapy effect prediction for node negative breast 
cancers.
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6.  GENERAL DISCUSSION AND FUTURE DIRECTIONS 
6.1 General remarks
In patients under 71 years old with operable lymph node negative breast cancer, the current 
trend is to use increasingly integrated models of clinical and molecular quantitative 
pathological data for prognostic and predictive models and therapeutic decision making. The 
most accurate assessment of established markers should be key features for a choice of useful 
treatment.  
6.2 Gene expression arrays 
The development of sophisticated technologies, such as gene expression arrays, 
permitting simultaneous measurement of thousands of genes to create a molecular portrait of 
the tumour, has identified molecular signatures, such as the 21-gene recurrence score (RS, 
Oncotype Dx®) or the Amsterdam 70-gene prognostic profile (Mammaprint®), that augment 
conventional prognostic indicators in their ability to predict breast cancer outcome and 
response to treatment particularly in identifying good- and poor-risk tumours within ER-
positive disease. The clinical value of these profiles for ER-negative disease is less clear (30) 
(Table 2). 
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Table 2.  Charcteristics of several well-known genomic profiles. 
ER:  Estrogen Receptor;  LN:  Lymph Node;  FFPE:  Formaldehyde Fixed Parafin 
Embedded; FDA:  Food and Drug Administration (USA);  TAM:  Tamoxifen;  AST:  
Adjuvant Systemic Treatment; Certif: Certification 
   
The Recurrence Score (RS) of Oncotype Dx® was developed using a different 
approach from the supervised analyses of gene expression arrays used by the 70-gene and 76-
gene profile developers (discussed below). In this approach, the investigators started with the 
250 most promising candidate genes selected from the literature. They used a reverse 
transcription polymerase chain reaction (RT-PCR)-based method for generating quantitative 
expression levels of these genes in fixed tissue from 447 patients collected from three largely 
hormone receptor-positive, node-negative datasets. The result is the RS, which is actually a 
mathematical formula that includes 16 genes (of which 10 are proliferation associated) 
weighted to optimize prediction of distant relapse despite tamoxifen therapy (31). It is among 
the best-validated prognostic assays, has some value in predicting chemotherapy response, 
and is relatively unique in that it can be used in fixed tissue. It is recommended by the 
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American Society of Clinical Oncology (ASCO) for use in women with node-negative, 
estrogen receptor (ER)-positive breast cancer (32).
The RS was validated in an independent dataset derived from 668 samples (from a 
total of 2617) collected in the tamoxifen-treated arm of National Surgical Adjuvant Breast 
and Bowel Project (NSABP) B-14, a prospective randomized clinical trial examining the 
benefit of adjuvant tamoxifen in hormone receptor-positive, node-negative breast cancer 
(31). Study participants were largely postmenopausal (71 percent), stage I (62 percent), and 
with a good prognosis (85 percent free of distant metastasis at 10 years). Although this 
population had a generally good prognosis, reflecting the low stage and treatment with 
tamoxifen, the RS was able to distinguish prognostic groups: of those with low RS (<18), 93 
percent were free of distant disease compared with only 70 percent of those with high RS 
(>31). Further analysis has shown the RS to be predictive of locoregional recurrence as well 
as distant recurrence (33). Similar findings have been reported with aromatase inhibitors in 
postmenopausal women (34), and it appears to identify relative benefit of chemotherapy 
across nonanthracycline, anthracycline, and anthracycline/taxane-based regimens (35-37). 
This usefulness is relatively clear at the extremes of the RS, but there is uncertainty with 
intermediate RS. The ongoing TAILORx trial (Figure 4) is expected to provide high-level 
evidence for the role of the RS in identifying those who may and those who may not benefit 
from chemotherapy (38). 
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Figure 4.  Randomized trial design for TAILORx (Trial Assigning IndividuaLized Options 
for Treatment Rx, from reference 38). 
The Mammaprint® (Amsterdam 70-gene profile) was the first in-vitro diagnostic 
multivariate index assay to be approved by the US Food and Drug Administration (FDA) in 
2007. It is an array-based prognosticator and classifies tumors as low-risk or high-risk for 
breast cancer recurrence. The test result, a binary score (low-risk and high-risk), is then 
derived through an algorithm based upon gene expression. A supervised analysis of the gene 
expression arrays on 98 breast tumor samples (80 % were from lymph node-negative women 
younger than 55 years, of whom 44 % had developed distant metastasis within five years), 
selected a 70-gene set with 83 percent accuracy at differentiating those with distant relapse 
versus those without (39).  
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The first validation study was a retrospective analysis from the same institution of 
295 patients, who were also young (less than 53 years at diagnosis), with T1 and T2 tumors, 
node-negative (151 patients) or node-positive (144 patients), treated with heterogeneous 
adjuvant therapy, and followed for nearly seven years (40). This analysis found a strong 
correlation between the "good" or "bad" 70-gene signature and likelihood of distant 
recurrence or death in multivariable analysis; however, it was criticized because of the bias 
introduced by the inclusion in this study of patients from the original set used to create the 
profile. 
A subsequent validation study used a truly independent patient cohort of 302 women; 
patients were under age 60, had node-negative T1 to T2 tumors, were treated without 
adjuvant systemic therapy, and were followed for over 10 years (41). The 70-gene signature 
performed independent of clinical variables in predicting time to distant metastasis (hazard 
ratio, HR 2.13) and overall survival (HR 2.63), but not disease-free survival (HR 1.36) (41). 
Patients in the gene signature high-risk group had a 10-year overall survival of 70 percent 
versus 90 percent for patients in the gene signature low-risk group.
The primary objectives of the MINDACT (Microarray In Node-negative and 1-3 
positive lymph- node Disease may Avoid ChemoTherapy) trial is to better select T1-3N0-3
breast cancer patients for adjuvant chemotherapy and hopefully thereby reduce the number of 
patients exposed to short and long term side effects of unnecessary cytotoxic treatments. It is 
a prospective multicentre randomized phase III study comparing the 70-gene signature with 
the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in 
breast cancer with 0-3 positive nodes (42).   
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The two other main objectives of the study address questions related to adjuvant 
treatment of breast cancer. MINDACT will compare anthracycline-based chemotherapy 
regimens to a docetaxel-capecitabine regimen and investigate the efficacy and safety of  
endocrine therapy with a 7 years single agent Letrozole to the sequential strategy of 2 years 
of Tamoxifen followed by 5 years of Letrozole (Randomisation-Endocrine therapy, see 
Figure 5). 
Figure 5.  Randomized trial design for MINDACT (Microarray In Node-negative and 
1-3 positive lymph- node Disease may Avoid ChemoTherapy, from reference 42). 
The Rotterdam 76-gene prognostic signature was developed in a test set of 115 
node-negative primary breast cancers from women who did not receive adjuvant therapy and 
had been followed for more than eight years (43). Recognizing the genetic heterogeneity of 
breast cancer, separate prognostic gene sets were developed for ER-negative (ER-, 16 genes) 
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and ER-positive (ER+, 60 genes) disease. The 76 prognostic genes were validated in an 
independent set of 171 mixed ER+ (75%) and ER- (25%) tumors, demonstrating 93 percent 
sensitivity and 48 percent specificity. In multivariate analysis of distant metastasis-free 
survival, the 76-gene prognostic indicator was independent of clinical variables (43). 
In a 198-patient subset of the 302 node-negative patients used in a validation study of 
the 70-gene profile (Mammaprint®, described above), the 76-gene prognostic signature 
demonstrated independent value (44). 
A major drawback of both the Mammaprint® and The Rotterdam signature is the 
need for fresh-frozen tissue.  It is also noteworthy that the validation studies highlight the 
time dependence of these signatures, using early relapse as the endpoint; they predict early 
relapse far better than late relapse (>5 years). The biology of late relapse might differ from 
early relapse and has been inadequately studied. 
A number of other signatures are under development. One of the most promising is 
the two-gene signature (HOX13:IL17BR). It was developed from 60 node-positive, hormone 
receptor-positive tumors and has been shown to predict breast cancer recurrence and 
endocrine therapy sensitivity (45). The antiapoptotic homeobox B13 (HOXB13) gene was 
associated with recurrence, while interleukin 17 receptor B (IL17BR) was associated with 
remaining disease free, making the ratio even more strongly associated with recurrence, with 
an adjusted odds ratio of approximately 7. However, various efforts to examine this signature 
in fixed tissue have yielded mixed results. 
Gene expression assays are costly, require much more cancer tissue than the 
molecular quantitative data (like MAI, PPH3, Ki67, ER, PR, HER2 and CK5-6), the 
47
prognosis prediction is not better than with MAI and PPH3 (Figure 6), and overtreatment is 
much worse (see Figure 7). 
Figure 6. The Overall (disease specific) survival rates in the prospective study of the 
Mammaprint® 70- gene signature (41) (left) and from the prospective MMMCP study of the 
Mitotic Activity Index, adapted from reference13 (right). Note the similarity in the survival 
rates. 
Figure 7. a) The real deaths of metastatic disease in node-negative operable breast cancer 
patients (data of the prospective MMMCP study from reference 13).  b) The number of 
patients classified as high risk by the Mitotic Activity Index, and c) the 70-gene signature 
mRNA Mammaprint® test (adapted from reference 41). 
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The Mammaprint® overtreats many more patients than the MAI with a threshold of 
10 (see Table 3). 
Table 3. Summary of survival rates of node-negative breast cancer according to gene 
expression signatures and Mitotic Activity Index.  
Mammaprint® 
70-gene signature 
(from reference 41) 
Mitotic Activity Index 
(MAI) 
(from reference 13) 
Number 198 516 
Number and incidence (%) 
Good Signature/MAI<10 55 (28%) 299 (58%) 
Poor Signature/ MAI10 143 (72%) 217 (42%) 
Overall Survival 10 years  
Good Signature/ MAI<10 92% 92% 
Poor Signature/ MAI10 72% 65% 
Difference Good and Poor 
signature/MAI<10 and MAI10 20% 27% 
The abovementioned data show that the Mammaprint® gene expression array for 
prognosis prediction in node negative breast cancer is less good than the MAI test with a 
threshold of 10. We therefore do not agree that appropriate integration of molecular assays 
(46) add power to the prognostic model obtained by the proliferation biomarkers described 
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by others (47), and also in the current thesis. Few studies have dealt with the methodological 
issues, such as sampling strategies, intratumour heterogeneity and reproducibility, as most 
studies are retrospective and thresholds vary.  
However, that does not take away that gene expression arrays will not be important. 
Medical oncologists are increasingly interested in the effect of certain therapies, rather than 
prognosis in general. Is a tumour sensitive to a certain treatment? Such questions are 
increasingly asked to the pathologist and if the pathology laboratory does not give such 
answers, this role is taken over by other specialized laboratories. Pathology laboratories 
should equip themselves with adequate technology to give such answers, if they wish to 
survive rather than be marginalized.   
   6.3 Standardization, Automation, Validation 
In our view, for breast cancer patients under 71 years, quantitative in situ proliferation 
markers MAI, PPH3 and Ki67, are the best predictors of outcome. The remaining problem is 
standardization. It has been shown that the MAI can be well reproducible when the MMMCP 
guidelines for tissue processing, staining, and MAI counts are strictly kept. However, this 
cannot be standardized and depends on the efforts of many technicians and pathologists 
worldwide.    
As long as there are no (inter)national guidelines with external quality control 
programs, and penalties on violation, strictly controlled standards and automated machines 
for tissue processing, tissue section thickness measurement, antigen retrieval, staining, and 
automated assessment of the proliferation markers, there is little hope that the molecular 
quantitative pathological criteria will be accepted worldwide. The professional and medical 
organizations in the past 3 decades have failed to achieve these goals. Since certain 
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pharmaceutical companies have entered the pathology market in 2009, Ki67 has suddenly 
been accepted as a treatment criterion, in spite of lack of Quality Control and Assessment, or 
any guidelines for the assessment of the Ki67 expression.  
In our laboratory, we assess MAI using the strict MMMCP protocol, and PPH3 and 
Ki67 by strictly protocolized automated immunohistochemistry and digital image processing. 
The quality of our IHC-assessments is continuously validated by participation in the 
NORDIQC external Quality Control program. However, validation studies between different 
pathology laboratories are largely lacking and mandatory before serious (inter)national 
conclusions can be drawn from the results of molecular pathology findings determined 
without such protocols. Unfortunately, such validations are largely lacking, both in Norway 
and outside. It is somewhat surprising that neither the Norwegian Pathology Society nor the 
European Society of Pathology have initiated such projects which are essential for the 
reliability of pathology determinations.  
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6.4 Elderly breast cancer patients 
It seems that breast cancers in patients >70 years react differently from those in 
younger women.The biologic characteristics of breast cancers change as age increases. 
Tumors in older patients are more likely to be hormone receptor positive, HER-2 negative, 
lymph node negative, and p53 negative and have lower grade with lower proliferation indices 
(5, 48, 49) (Figure 8) 
Figure 8. The prognostic value of proliferation in lymph node-negative breast cancer 
patients is age dependent (from reference 5). 
However, very little serious research has been carried out, in spite of the fact that in 
the coming decades many more patients with breast cancer will be over 70 years of age at the 
time of diagnosis. Future studies should concentrate on unravelling the biology of breast 
cancers in this age group. 
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6.5 Insulin and Insulin growth Factor Receptor 
There is increasing evidence that insulin, as an important effector of diet and life-
style plays an important role in the development and progression of breast cancer (50 ), The 
findings are biologically plausible, circulating IGF1 concentration is associated with 
previously known risk factors for breast cancer for which the underlying physiological basis 
was unclear, such as height, age at menarche, and mammographic breast density, suggesting 
that these may be linked to risk, at least in part, because they act as surrogates for IGF1 
concentration (51). Quanititative in situ analysis of Insulin and Insulin Growth Factor 
receptors seems utterly important.  
6.6 Lymph node positive patients 
Another important research aspect is patients with limited node positive breast cancer 
(1, 2 and 3 positive lymph nodes). These are increasingly important as patients with 
extensive nodal metastases are decreasing. It may be that patients with 1 positive lymph 
node, behave similar to node negative patients and may require less chemotherapy. The 
influence of the sentinel-node method on lymph node status should also be evaluated.
  6.7 microRNA and proteomics 
Finally, alternative techniques could be considered. We will discuss two methods: 
microRNA and Proteomics.  
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Recently an extra level of gene regulation was discovered: small non-coding RNA 
molecules called microRNA’s (miRNA). They play an important role in gene-silencing by 
binding directly and specifically to mRNA molecules. miRNAs are 19-25 nucleotides in 
length and compose the largest family of non-coding RNA’s involved in gene silencing. 
Their functions are exerted through translational inhibition of the targeted mRNA by binding 
to the 3'-UTR (imperfect match) and degradation of target mRNA (perfect match) (52) 
miRNAs are down-regulated in a number of different tumours (53, 54), and in some cases 
the re-introduction of these miRNAs has been shown to impair the viability of cancer cells 
(55).  
We and others have recently shown that miRNA can be useful. In a recent study, 
Janssen et al (56) studied the miRNA pattern in 103 lymph node negative breast cancer and 
compared these profiles with different biologic characteristics and clinicopathologic features. 
Unsupervised hierarchical cluster analysis divides the patients in 4 main groups, of which the 
basal-like/TNP group is the most prominent (11% of all cases). The luminal A cancers 
containing the HER2 negative and ER/PR-positive tumours is the largest group (57%) and 
the group of luminal B (32%) is more heterogeneous and contains the HER2 positive/ER-
negative patients as well. The highest overall classification values by ANOVA analysis 
followed by cross validation (leave one sample out and reselect genes) were found for CK5-
6, TNP and ER, with 97%, 90% and 90% accuracy. MiR-106b is prominently present in all 
of these signatures and correlates strongest with high proliferation. Other interesting 
observations are the presence of several miRNAs (miR532-5p, miR-500, miR362-5p, and 
miR502-3p) located at Xp11.23 in cancers with a TNP signature and the upregulation of 
several miR-17 cluster members in ER-negative tumours. The study showed that ER 
negativity and CK5-6 expression are important and specific biologic processes in lymph 
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node negative breast cancer as the correlations with specific microRNAs are strongest in the 
ER-negative and CK5-6 positive tumours. miRNA analysis in breast cancer therefore seem 
promising. However, topics such as test reproducibility, and sampling variations still have to 
be studied. In how far does tumour heterogeneity interfere with the results? Is there a 
difference between the center and the periphery, and what about small and large tumours? 
Are metastatic deposits different from the primary tumours? Such studies are largely lacking 
and must be undertaken before the methods can be taken into routine use. 
The proteome, or protein composition, determines the functional state of a cancer. 
Expression of proteins between different diagnostic or prognostic groups can be detected by 
analysis of their proteins but may not be detectable by genomic analysis.  
Proteomic analysis offers the possibility to compare protein abundance in almost any 
sample type. Proteomics has been applied to breast cancer for some time. Recent studies 
show promising results (57, 58).  
SELDI-TOF mass spectrometry, where proteins are bound to a chromatographic chip and 
then analyzed, is a high-throughput method utilized to obtain protein profiles that can be 
used to compare sample groups. Unfortunately, the formaldehyde-fixed paraffin embedding 
(FFPE) procedure of biopsies destroys water-soluble proteins (59). Our group has recently 
described a method that can save and extract water soluble proteins from punch biopsies. It 
was shown that protein collection method for biopsy samples can further help to define the 
diagnosis and behavior of Cervical Intraepithelial Neoplasia (CIN) lesions. The fresh 
biopsies are placed in a RPMI1640 medium for 24 hours at 4oC, after which the biopsies 
were used for routine histological examination. The method resembles the one published by 
Celis et al (60). We have also shown that a panel of 3 peaks from SELDI-TOF protein 
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profiles can be used to differentiate normal tissue from CIN tissue samples and that a 
discrimination of CIN2 and CIN3 lesions could be obtained using cytokeratin 2 (61). 
Moreover, Zinc-finger protein 441 and Phospholipase D6 detected by proteomic LC-MS 
(LTQ-Orbitrap) in supernatant samples from a water-soluble protein-saving punch biopsy 
processing method can predict regression of CIN2-3 (46). It would be highly interesting to 
evaluate the same method in breast cancer.  
56
7.  REFERENCES 
1. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ et al. 
Meeting highlights: updated international expert consensus on the primary therapy of 
early breast cancer. J Clin Oncol 2003; 21:3357-3365. 
2. Early Breast Cancer Trialists’ Collaborative Group (EBCTG): Effects of 
chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-
year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717. 
3. Adjuvant! Online http://www.adjuvantonline.com (Accessed on Sept. 30, 2011). 
4. Boyages J, Chua B, Taylor R, et al. Use of the St Gallen classification for patients 
with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br 
J Surg 2002; 89:789-796. 
5. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, et al. 
The prognostic value of proliferation in lymph-node-negative breast cancer patients 
is age dependent. Eur J Cancer 2007 Feb; 43(3):527-535. 
6. Baak JP, Wisse-Brekelmans EC, Kurver PH, van Gorp LH, Voorhorst FJ, Miettinen 
OS. Regional differences in breast cancer survival are correlated with differences in 
differentiation and rate of proliferation. Hum Pathol 1992 Sep; 23(9):989-992. 
7. Volpi A, De Paola F, Nanni O, Granato AM, Bajorko P, Becciolini A et al. 
Prognostic significance of biologic markers in node-negative breast cancer patients, 
a prospective study. Breast Cancer Res Treat 2000 63;181–192. 
8. Lende TH, Janssen EAM, Gudlaugsson E, Voorhorst FJ, Smaaland R, van Diest P, 
Søiland H, Baak JPA.  In patients younger than age 55 years with lymph node-
57
negative breast cancer, proliferation by mitotic activity index is prognostically 
superior to Adjuvant!. J Clin Oncol 2010; 29(7):852-858. 
9. Norwegian Breast Cancer Group: Treatment guidelines 
http://www.nbcg.no/adjuvant_behandling/NBCGs%.pdf (Accessed on Oct. 18, 
2011). 
10. Skaland I, Janssen EA, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H, et al. 
Phosphohistone H3 expression has much stronger prognostic value than classical 
prognosticators in invasive lymph node-negative breast cancer patients less than 55 
years of age. Mod Pathol 2007 Dec; 20(12):1307-15. 
11. Kaman EJ, Smeulders AW, Verbeek PW, Young IT, Baak JP. Image processing for 
mitosis in selections of breast cancer: a feasibility studt. Cytometry 1984; 5(3):244-
249. 
12. Belien JA, Copper MP, Braakhuis BJ, Snow GB, Baak JP. Standardization of 
counting micronuclei: definition of a protocol to measure genotoxic damage in 
human exfoliated cells. Carcinogenesis 1995; 16(10):2395-2400. 
13. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB et al. 
Prospective multicenter validation of the independent prognostic value of the mitotic 
activity index in lymph node-negative breast cancer patients younger than 55 years. J 
Clin Oncol 2005; 23(25):5993-6001. 
14. Norwegian Cancer Registry: “Cancer in Norway 2009” 
http://www.kreftregisteret.no/forekomst_og_overlevelse (Accessed on Oct. 10, 
2011). 
58
15. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ; Panel 
members. Strategies for subtypes-dealing with the diversity of breast cancer: 
highlights of the St. Gallen international expert concensus on the primary therapy of 
early breast cancer 2011. Ann Oncol 2011; 22(8):1736-1747. 
16. Desmedt C, Sotiriou C. Proliferation: the most prominent predictor of clinical 
outcome in breast cancer. Cell Cycle 2006; 19:2198-2202. 
17. Van Diest PJ, Baak JPA, Matze-Cok P, Wisse-Brekelmans EC, van Galen CM, 
Kurver PH, et al. Reproducibility of mitosis counting in 2469 breast cancer 
specimens, results from the multicentre morphometric mammary carcinoma project. 
Hum Pathol 1992; 23:603–607. 
18. Janssen EAM, van Diest PJ , Søiland H, Gudlaugson E, Nysted A, Voorhorst FJ, et 
al. Success factors of adjuvant chemotherapy in node-negative breast cancer patients 
under 55 years. Cellular Oncology 2006; 28(5-6):295-303. 
19. Amadori D, Nanni O, Marangolo M, Pacini P, Ravaioli A, Rossi A, et al. Disease-
free survival advantage of adjuvant cyclophosphamide, methotrexate, and 
fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a 
randomized multicenter study. J Clin Oncol 2000; 18:3125-3134. 
20. Fiets WE, Bellot FE, Struikmans H, Blankenstein MA, Nortier JW.  Prognostic 
value of mitotic counts in axillary node negative breast cancer patients with 
predominantly well-differentiated tumours. Eur J Surg Oncol 2005; 31(2):128-133. 
21. Westenend PJ, Meurs CJ, Damhuis RA. Tumour size and vascular invasion predict 
distant metastasis in stage I breast cancer. Grade distinguishes early and late 
metastasis. J Clin Pathol 2005; 58(2):196-201.  
59
22. Hall PA, Going JJ. Predicting the future, a critical appraisal of cancer prognosis 
studies. Histopathology 1999; 35:489–494. 
23. Baak JP. The framework of pathology, good laboratory practice by quantitative and 
molecular methods. J Pathol 2002; 198(3):277-283. 
24. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, Eusebi V, et al. 
Invasive breast carcinoma, in Tavassoli FA and Devilee P (ed): Pathology and 
Genetics of Tumours of the Breast and Female Genital Tract Organs. Lyon, IARC 
Press, 2003, pp 13-48. 
25. Goldstein DJ. Aspects of scanning microdensitometry. I. Stray light (glare). J 
Microsc 1970; 92:1-16. 
26. Elias H, Hyde DM. An elementary introduction to stereology (quantitative 
microscopy). Am J Anat 1980; 159:412-446. 
27. Bossard C, Jarry A, Colombeix C et al. PPH3-based phosphohistone PPH3 labelling 
for histoprognostic grading of  breast adenocarcinomas and computer-assisted 
determination of mitotic index. J Clin Pathol 2006; 59:706-710. 
28. Baak JP. Manual of quantitative pathology in cancer diagnosis and prognosis.  
Berlin, Heidelberg, New York, Springer-Verlag, 1991. 
29. Skaland I, Janssen EAM, Gudlaugsson E, Klos J, Kjellevold KH, Søiland H, Baak 
JPA. Validating the prognostic value of proliferation measured by Phosphohistone 
H3 (PPH3) in invasive lymph node-negative breast cancer patients less than 71 years 
of age. Breast Cancer Res Treat 2009; 114:39-45. 
60
30. Carey LA. Prognostic molecular profiles of breast cancer http://www.uptodate.com 
(Accessed on Oct. 25, 2011). 
31. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-
treated, node-negative breast cancer. N Engl J Med 2004; 351:2817 
32. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 
update of recommendations for the use of tumor markers in breast cancer. J Clin 
Oncol 2007; 25:5287. 
33. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence 
score assay and risk of locoregional recurrence in node-negative, estrogen receptor-
positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 
2010; 28:1677. 
34. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 
21-gene recurrence score in node-negative and node-positive postmenopausal 
patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC 
study. J Clin Oncol 2010; 28:1829. 
35. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in 
women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 
2006; 24:3726. 
36. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-
gene recurrence score assay in postmenopausal women with node-positive, 
61
oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis 
of a randomised trial. Lancet Oncol 2010; 11:55. 
37. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded 
core biopsy tissue predict response to chemotherapy in women with locally advanced 
breast cancer. J Clin Oncol 2005; 23:7265. 
38. Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal 
Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously 
Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for 
Recurrence (TAILORx Trial) http://www.cancer.gov/clinicaltrials/ECOG-PACCT-1 
(Accessed on May 25, 2011). 
39. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts 
clinical outcome of breast cancer. Nature 2002; 415:530. 
40. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a 
predictor of survival in breast cancer. N Engl J Med 2002; 347:1999. 
41. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene 
prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 
2006; 98:1183. 
42. A prospective randomized study comparing the 70-gene signature with the common 
clinical-pathological criteria in selecting patients for adjuvant chemotherapy in 
breast cancer with 0-3 positive nodes (EORTC Trial 10041 (BIG 3-04)-MINDACT) 
http://www.eortc.be/service/unit/mindact/MINDACT_websiteii.asp (Accessed on 
Oct. 25, 2011). 
62
43. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant 
metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365:671. 
44. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic 
signature for node-negative breast cancer patients in the TRANSBIG multicenter 
independent validation series. Clin Cancer Res 2007; 13:3207. 
45. Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical 
outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5:607. 
46. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 
2009; 360:790–800. 
47. Viale G. Integrating molecular profiling, histologic type and other variables: defining 
the fingerprint of responsiveness to treatment. Breast 2009; 18(Suppl 1):S3. (Abstr 
S8).  
48. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of 
elderly women with breast cancer. J Natl Cancer Inst 2000; 92:550-556.  
49. Eppenberger-Castori S, Moore DH Jr, Thor AD, et al. Age-associated biomarker 
profiles of human breast cancer. Int J Biochem Cell Biol 2002; 34:1318-1330. 
50. Pollak M. Insulin-like growth factor-related signaling and cancer development. 
Resent Results Cancer Res 2007; 174:49-53. 
63
51. Pollak M, MJ Blouin, JC Zhang and JJ Kopchick, Reduced mammary gland 
carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J 
Cancer 2011; 85:428–430. 
52. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 
23: 116(2):281-97. 
53. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some 
microRNAs downregulate large numbers of target mRNAs. Nature 2005; 433(7027): 
769-73. 
54. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for 
normal immune function. Science 2007; 316(5824): 608-11. 
55. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor 
suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26(34): 
5017-22. 
56. Janssen EA, Slewa A, Gudlaugsson E, Jonsdottir K, Skaland I, Søiland H, Baak JP. 
Biologic profiling of lymph node negative breast cancer by means of microRNA 
expression. Mod Pathol 2010; 23(12):1567-1576. 
57. Gonzales-Angulo AM, Hennessy BT, Meric-Bernstam F, et al. Functional 
proteomics can define prognosis and predict pathologic complete response in 
patients with breast cancer. Clin Proteomics 2011; 8(1):11. 
58. Röwer C, Ziems B, Radtke A, et al. Toponostics of invasive ductal breast carcinoma: 
combination of spatial protein expression imaging and quantitative proteome 
signature analysis. Int J Clin Exp Pathol 2011; 4(5):454-467. 
64
59. Uleberg KE, Munk AC, Brede C, Gudlaugsson E, van Diermen B, Skaland I, 
Malpica A, Janssen EA, Hjelle A, Baak JP. Discrimination of grade 2 and 3 cervical 
intraepitelial neoplasia by means of analysis of water soluble proteins recovered 
from cervical biopsies. Proteome Sci 2011; Jun 28; 9:36. 
60. Celis JE, Gromov P, Cabezon T, Moreira JM, Ambartsumian N, Sandelin K, 
Rank F, Gromova I. Proteomic characterization of the interstitial fluid 
perfusing the breast tumor microenvironment: a novel resource for biomarker 
and therapeutic target discovery.  Mol Cell Proteomics 2004; 3:327-344. 
61. Uleberg KE, Munk AC, Furlan C, van Diermen B, Gudlaugsson E, Janssen E, 
Malpica A, Hjelle A, Baak JP: A Protein Profile Study to Discriminate CIN 
Lesions from Normal Cervical Epithelium. Cellular Oncology 2011; May 15 
[Epub ahead of print]. 
